Development of farnesyl transferase inhibitors: a review.
about
Cancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentGenomic alterations in pancreatic cancer and their relevance to therapySignal transduction inhibitors in treatment of myelodysplastic syndromesActivation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.Intracellular oxygen determined by respiration regulates localization of Ras and prenylated proteins.Targeting the RAS oncogene.A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimeticsA RasGAP SH3 peptide aptamer inhibits RasGAP-Aurora interaction and induces caspase-independent tumor cell deathChemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasisDiabetes regulates small molecular weight G-protein, H-Ras, in the microvasculature of the retina: implication in the development of retinopathyIdentification of a farnesol analog as a Ras function inhibitor using both an in vivo Ras activation sensor and a phenotypic screening approach.The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation and preliminary mechanism study.Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitorsMAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice.Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds databaseClinical relevance of KRAS in human cancers.Ras in cancer and developmental diseasesRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Kras as a key oncogene and therapeutic target in pancreatic cancerTargeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.A farnesylated G-protein suppresses Akt phosphorylation in INS 832/13 cells and normal rat islets: regulation by pertussis toxin and PGE₂.Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsLonafarnib is a potential inhibitor for neovascularization.A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzymeTipifarnib and tanespimycin show synergic proapoptotic activity in U937 cellsRelevant molecular markers and targets.Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activationPotential biological functions of cytochrome P450 reductase-dependent enzymes in small intestine: novel link to expression of major histocompatibility complex class II genes.Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparumA phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).Personalized medicine and treatment approaches in non-small-cell lung carcinoma.Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.Onco-Golgi: Is Fragmentation a Gate to Cancer Progression?Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy
P2860
Q26740619-78987C03-9FEC-4593-9A7B-3C971F73A81AQ26781443-1441287B-8883-4285-9933-8FF209F12D4CQ26829903-BE0BE77B-7D37-428E-BA55-B0FD088124C4Q27308683-827E51E6-E978-48B2-9C1A-8CF327A18B51Q27318713-D35ABE82-450C-4C06-9366-B8C8ECD24803Q27329552-760F0028-E940-470D-9BFC-F9178B2C047BQ27687198-DCD48A1B-067B-4B21-BA45-7BC7EFEE8ACFQ28382899-C76D4F56-7710-409D-8EAD-6D0D534C24D3Q28473249-80EC29E6-3464-418A-BACC-5CC710BCECAAQ28539314-9733818C-488D-49CF-9513-802446E5E03DQ28577516-37F323C0-033F-4891-B6FC-580783D3490BQ30573674-E8D87AC6-9EFA-4146-9C6D-B9DB3F2B85D1Q33648593-1408F57E-99CC-4C3F-A5D9-4AE21F570E98Q33669995-7209A75F-74DF-4D72-BAD6-FDABED4CBE38Q33680759-C118F6CA-C9CF-4195-B6E4-A5E7E0331771Q33691759-93171C5E-7FA8-49C9-BE19-D3A3085C6CC6Q33828022-7AC984BC-617F-4B57-B016-8778E6E00ECEQ33959887-22E3A067-EE39-40D5-99E4-FF44A14A2D70Q34202697-2A700908-BCDE-4165-AFEB-97449D297B66Q34307356-2DEDA72E-602D-4E19-99E0-0A7CD287ECB4Q34659332-10131F06-2762-4266-955E-07E753F43363Q34659415-23C9E8C4-9AB6-4666-94D9-7B22FD7A8E27Q34884341-2EE809EB-D63D-4125-960C-3C8E12D2A852Q35012724-42834833-3B3D-4407-B341-D2719B29961EQ35043887-7E6BE0A7-41A6-4C0F-B51E-50FF2B7CA745Q35324064-14FAEE85-D31B-4C83-96A3-4E7FFA9C19FBQ35537834-BF9C6459-ED9D-48AA-9B17-1F71133E837CQ35590750-9E175ED1-7476-44CC-AE2D-C536B7F9BA17Q35754391-306E213F-5F5D-410A-B1C8-7868392FF640Q35791117-5701A1BD-5596-4BDC-82F1-523C9E085CE2Q35828643-BED3371E-E2AA-470B-BF42-C69ADB10511CQ36007003-4A65C700-DE97-4DFC-A9E7-67061E9DB393Q36050896-D8AF3B53-1AFB-4F1C-9DBB-C7426AC88CF1Q36132957-04FBC75A-7E2B-458E-93B6-92670506B24CQ36441548-9D93F519-F780-444A-9004-C141DA7CFB25Q36458731-50BF96F9-7933-4EE0-A524-2AAECD0DB479Q36740646-6E952C9C-C81C-472E-AF6E-AEDB55C8D4B7Q36753692-AD73DB00-FB4F-47BC-B0C2-D263E7FF2C37Q36776494-655B67E0-835B-4672-824B-599AC516093DQ36782324-23BA0199-60DD-42CA-B145-E0195ACAE408
P2860
Development of farnesyl transferase inhibitors: a review.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Development of farnesyl transferase inhibitors: a review.
@ast
Development of farnesyl transferase inhibitors: a review.
@en
type
label
Development of farnesyl transferase inhibitors: a review.
@ast
Development of farnesyl transferase inhibitors: a review.
@en
prefLabel
Development of farnesyl transferase inhibitors: a review.
@ast
Development of farnesyl transferase inhibitors: a review.
@en
P2093
P1433
P1476
Development of farnesyl transferase inhibitors: a review.
@en
P2093
Jan H M Schellens
Jos H Beijnen
Natalie M G M Appels
P304
P356
10.1634/THEONCOLOGIST.10-8-565
P577
2005-09-01T00:00:00Z